Extensive-stage SCLC: Clinical Trials

1 trial for Extensive-stage SCLC, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 recruiting. 1 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 11Recruiting 1
Phase 21Recruiting 1

Follow Extensive-stage SCLC: new trials by email Literature Review of Extensive-stage SCLC trials Research Report on Extensive-stage SCLC

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
EB-DART-NK01, Lymphodepleting chemotherapy - Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC
Phase 1 / Phase 2RecruitingBeijing Biotech602026-03-022026-08-04

Narrower conditions

Recurrence (1)  ·  Small Cell Lung Carcinoma (1)

Broader conditions

Bronchial Neoplasms (1)  ·  Carcinoma, Bronchogenic (1)  ·  Disease Attributes (1)  ·  Lung Diseases (1)  ·  Lung Neoplasms (1)  ·  Neoplasms (1)  ·  Neoplasms by Site (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Respiratory Tract Diseases (1)  ·  Respiratory Tract Neoplasms (1)  ·  Thoracic Neoplasms (1)

Sponsors

Beijing Biotech (1)

Countries

China (1)